Loncar Cancer Immunotherapy ETF (CNCR)
- Previous Close
14.36 - Open
14.30 - Bid 14.01 x 500
- Ask 14.29 x 500
- Day's Range
13.92 - 14.46 - 52 Week Range
9.22 - 17.96 - Volume
14,954 - Avg. Volume
38,277 - Net Assets 28.75M
- NAV 14.41
- PE Ratio (TTM) --
- Yield 0.00%
- YTD Daily Total Return 6.61%
- Beta (5Y Monthly) 0.89
- Expense Ratio (net) 0.79%
The index was established in 2023 by Range Fund Holdings and tracks the performance of a portfolio of U.S. exchange-listed pharmaceutical or biotechnology stocks or American Depositary Receipts (“ADRs”) with a market capitalization of more than $250 million. The advisor attempts to invest all, or substantially all, of its assets in the component securities that make up the index. Under normal circumstances, at least 80% of the fund’s total assets will be invested in the component securities of the index.
Loncar Investments
Fund Family
Health
Fund Category
28.75M
Net Assets
2015-10-13
Inception Date
Performance Overview: CNCR
Trailing returns as of 4/18/2024. Category is Health.
People Also Watch
Holdings: CNCR
Top 10 Holdings (27.17% of Total Assets)
Sector Weightings
Recent News: CNCR
Research Reports: CNCR
Analyst Report: Netflix, Inc.
Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with almost 250 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
RatingBearishPrice TargetERF: What does Argus have to say about ERF?
ENERPLUS CORP has an Investment Rating of SELL; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingBearishPrice TargetERF: Raising target price to $16.00
ENERPLUS CORP has an Investment Rating of SELL; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingBearishPrice TargetERF: What does Argus have to say about ERF?
ENERPLUS CORP has an Investment Rating of SELL; a target price of $14.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingBearishPrice Target